摘要
目的探讨对脑出血后缺血性脑损伤患者选择尼莫地平药物治疗后获得的临床效果。方法选择该院2017年6月-2019年2月收治的113例脑出血后缺血性脑损伤患者作为实验对象;数字奇偶法分组后探究每组所用治疗药物;比照组(56例):选择依达拉奉展开病情治疗;实验组(57例):选择尼莫地平药物展开病情治疗;比较两组用药疗效、NIHSS(脑卒中评定结果量表)评定结果、Barthel(日常生活能力评定结果量表)评定结果以及用药不良反应结果差异。结果实验组脑出血后缺血性脑损伤患者用药总有效率(98.25%)高于比照组(80.36%)明显(χ^2=9.523 2,P<0.05);实验组用药前NIHSS评分为(22.75±3.43)分,用药后为(13.22±1.02)分;用药前Barthel评分为(38.75±10.25)分,用药后为(60.46±5.69)分;比照组用药前NIHSS评分为(22.65±3.42)分,用药后为(17.03±2.19)分;用药前Barthel评分为(38.73±10.25)分,用药后为(43.55±8.03)分;用药前,实验组脑出血后缺血性脑损伤患者NIHSS评定结果与Barthel评定结果同比照组比较差异无统计学意义(t=0.155 1,0.010 3,P>0.05);用药后,实验组脑出血后缺血性脑损伤患者NIHSS评定结果高于比照组明显,Barthel评定结果低于比照组明显(t=11.888 2,12.934 0,P<0.05);实验组脑出血后缺血性脑损伤患者用药不良反应发生率(3.51%)低于比照组(21.43%)明显(χ^2=8.356 9,P<0.05)。结论脑出血后缺血性脑损伤患者于临床接受尼莫地平药物治疗后,对于用药疗效的显著性提升,NIHSS评定结果的显著性降低,Barthel评定结果的显著性提升,用药副反应发生率显著性降低,均可有效促进,最终对于脑出血后缺血性脑损伤患者康复状态的提升,奠定基础。
Objective To investigate the clinical effects of nimodipine in patients with ischemic brain injury after cerebral hemorrhage. Methods A total of 113 patients with ischemic brain injury after cerebral hemorrhage were enrolled in our hospital from June 2017 to February 2019. The digital parity method was used to investigate the therapeutic drugs used in each group. The comparison group (56 cases): Select edaravone to start treatment;experimental group (57 cases): select nimodipine for drug treatment;compare the efficacy of two groups of medication, NIHSS (stroke assessment results scale) assessment results, Barthel (dietary life ability assessment results) Scale) assessment results and differences in drug side effects. Results The total effective rate of patients with ischemic brain injury after cerebral hemorrhage in the experimental group (98.25%) was significantly higher than that of the control group (80.36%)(χ^2=9.523 2,P<0.05). The pre-medication NIHSS score was (22.75±3.43) points, after treatment (13.22±1.02) points;Barthel score before treatment (38.75±10.25)points, after treatment (60.46±5.69) points;before the treatment group NIHSS score was (22.65±3.42) points, after treatment, the score was (17.03±2.19)points;the Barthel score before the treatment was (38.73±10.25)points, and the dose was (43.55± 8.03)points. Before the administration, the NIHSS evaluation results of the ischemic brain injury in the experimental group after cerebral hemorrhage Barthel's assessment results were not significantly different from the comparison group (t=0.155 1, 0.010 3,P>0.05). After administration, the NIHSS assessment results of patients with ischemic brain injury after cerebral hemorrhage in the experimental group were higher than those in the control group, and the Barthel evaluation results were lower than the results. The comparison group was significantly (t=11.888 2, 12.930 40,P<0.05);the incidence of drug side effects in patients with ischemic brain injury after cerebral hemorrhage in the experimental group (3.51%) was significantly lower than that in the control group (21.43%)(χ^2=8.356 9,P<0.05). Conclusion After the clinical treatment of nimodipine after cerebral hemorrhage, the clinical efficacy of the drug is significantly improved, the NIHSS assessment results are significantly lower, the Barthel assessment results are significantly improved, the incidence of drug side effects decrease significantly, which can be effectively promoted, and finally lays a foundation for the improvement of the rehabilitation state of patients with ischemic brain injury after cerebral hemorrhage.
作者
芮志华
RUI Zhi-hua(Department of Emergency, Baoshan People's Hospital, Baoshan, Yunnan Province, 678000 China)
出处
《世界复合医学》
2019年第6期57-60,共4页
World Journal of Complex Medicine
关键词
尼莫地平
脑出血后缺血性脑损伤
临床效果
Nimodipine
Ischemic brain injury after cerebral hemorrhage
Clinical effect
